86 related articles for article (PubMed ID: 16892363)
1. Design and synthesis of a PSMA inhibitor-doxorubicin conjugate for targeted prostate cancer therapy.
Jayaprakash S; Wang X; Heston WD; Kozikowski AP
ChemMedChem; 2006 Mar; 1(3):299-302. PubMed ID: 16892363
[No Abstract] [Full Text] [Related]
2. Prostate cancer-specific monoclonal antibody 5D4 significantly enhances the cytotoxicity of doxorubicin-loaded liposomes against target cells in vitro.
Sawant RM; Cohen MB; Torchilin VP; Rokhlin OW
J Drug Target; 2008 Aug; 16(7):601-4. PubMed ID: 18686131
[TBL] [Abstract][Full Text] [Related]
3. 1alpha,25-Dihydroxyvitamin D3 down-regulates expression of prostate specific membrane antigen in prostate cancer cells.
Serda RE; Bisoffi M; Thompson TA; Ji M; Omdahl JL; Sillerud LO
Prostate; 2008 May; 68(7):773-83. PubMed ID: 18247401
[TBL] [Abstract][Full Text] [Related]
4. Prostate-specific membrane antigen and its truncated form PSM'.
Mlcochová P; Barinka C; Tykvart J; Sácha P; Konvalinka J
Prostate; 2009 Apr; 69(5):471-9. PubMed ID: 19107881
[TBL] [Abstract][Full Text] [Related]
5. Prostate-specific antigen doubling time as a surrogate marker for evaluation of oncologic drugs to treat prostate cancer.
Kelloff GJ; Coffey DS; Chabner BA; Dicker AP; Guyton KZ; Nisen PD; Soule HR; D'Amico AV
Clin Cancer Res; 2004 Jun; 10(11):3927-33. PubMed ID: 15173102
[No Abstract] [Full Text] [Related]
6. Enzymatic activation of prodrugs by prostate-specific antigen: targeted therapy for metastatic prostate cancer.
Denmeade SR; Isaacs JT
Cancer J Sci Am; 1998 May; 4 Suppl 1():S15-21. PubMed ID: 9619266
[No Abstract] [Full Text] [Related]
7. Cytotoxic agents in prostate cancer: an enigma.
Yagoda A
Semin Urol; 1983 Nov; 1(4):311-21. PubMed ID: 6399617
[No Abstract] [Full Text] [Related]
8. Cooperative clinical trials in prostate cancer.
Murphy GP; Slack NH
Prog Clin Biol Res; 1981; 75B():341-6. PubMed ID: 7323102
[No Abstract] [Full Text] [Related]
9. Target-dependent T-cell activation by coligation with a PSMA x CD3 diabody induces lysis of prostate cancer cells.
Bühler P; Molnar E; Dopfer EP; Wolf P; Gierschner D; Wetterauer U; Schamel WW; Elsässer-Beile U
J Immunother; 2009; 32(6):565-73. PubMed ID: 19483653
[TBL] [Abstract][Full Text] [Related]
10. Amphipathic peptide-based fusion peptides and immunoconjugates for the targeted ablation of prostate cancer cells.
Rege K; Patel SJ; Megeed Z; Yarmush ML
Cancer Res; 2007 Jul; 67(13):6368-75. PubMed ID: 17616696
[TBL] [Abstract][Full Text] [Related]
11. Recombinant prostate-specific antigen proaerolysin shows selective protease sensitivity and cell cytotoxicity.
Singh R; Browning JL; Abi-Habib R; Wong K; Williams SA; Merchant R; Denmeade SR; Buckley TJ; Frankel AE
Anticancer Drugs; 2007 Aug; 18(7):809-16. PubMed ID: 17581303
[TBL] [Abstract][Full Text] [Related]
12. Prostate specific antigen (PSA) may be a poor marker for progression of prostate cancer after treatment with a combination of chemo-hormonal therapies.
Sartor O
J La State Med Soc; 2008; 160(2):99-100. PubMed ID: 18681353
[TBL] [Abstract][Full Text] [Related]
13. Novel concepts in androgen receptor blockade.
Hsieh AC; Ryan CJ
Cancer J; 2008; 14(1):11-4. PubMed ID: 18303477
[TBL] [Abstract][Full Text] [Related]
14. Prostate-specific membrane antigen expression as a predictor of prostate cancer progression.
Perner S; Hofer MD; Kim R; Shah RB; Li H; Möller P; Hautmann RE; Gschwend JE; Kuefer R; Rubin MA
Hum Pathol; 2007 May; 38(5):696-701. PubMed ID: 17320151
[TBL] [Abstract][Full Text] [Related]
15. Prostate cancer chemotherapy in the era of targeted therapy.
Michael A; Syrigos K; Pandha H
Prostate Cancer Prostatic Dis; 2009; 12(1):13-6. PubMed ID: 18521103
[TBL] [Abstract][Full Text] [Related]
16. Preclinical antitumor activity of the oral platinum analog satraplatin.
Wosikowski K; Lamphere L; Unteregger G; Jung V; Kaplan F; Xu JP; Rattel B; Caligiuri M
Cancer Chemother Pharmacol; 2007 Sep; 60(4):589-600. PubMed ID: 17541592
[TBL] [Abstract][Full Text] [Related]
17. Bone-targeted therapy: phase II study of strontium-89 in combination with alternating weekly chemohormonal therapies for patients with advanced androgen-independent prostate cancer.
Amato RJ; Hernandez-McClain J; Henary H
Am J Clin Oncol; 2008 Dec; 31(6):532-8. PubMed ID: 19060583
[TBL] [Abstract][Full Text] [Related]
18. Synthesis and stereochemical preference of peptide 4-aminocyclophosphamide conjugates as potential prodrugs of phosphoramide mustard for activation by prostate-specific antigen (PSA).
Jiang Y; Dipaola RS; Hu L
Bioorg Med Chem Lett; 2009 May; 19(9):2587-90. PubMed ID: 19345094
[TBL] [Abstract][Full Text] [Related]
19. A pilot dose-escalation study of the effects of nordihydroguareacetic acid on hormone and prostate specific antigen levels in patients with relapsed prostate cancer.
Ryan CJ; Harzstark AH; Rosenberg J; Lin A; Claros C; Goldfine ID; Kerner JF; Small EJ; Youngren JF
BJU Int; 2008 Feb; 101(4):436-9. PubMed ID: 18234062
[TBL] [Abstract][Full Text] [Related]
20. Drug uptake enhancement using sonodynamic effects at 4 MHz--a potential application for micro-ultrasonic-Transducers.
Siu T; Jackson J; Burt H; Chiao M
IEEE Trans Biomed Eng; 2007 Jun; 54(6 Pt 2):1153-6. PubMed ID: 17549907
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
